Skip to content
MARKETS / NYSE / OGEN
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Oragenics Inc. OGEN

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-9.8M
In brief

What this company does

The Company is currently focused on advancing the development and commercialization of its lead product candidate, ONP-002. Our lead product and focus are on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (“mTBI” or “Concussion”). The drug candidate is manufactured into a powder and filled into a novel intranasal device. We believe the proprietary powder formulation and intranasal administration allows for rapid and direct accessibility to the brain. As of December 31, 2025, we had three full-time and part-time employees.

Written from the business description in Oragenics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2023 · Revenue 0.0 · Net income -20.7
-8M-16M201020122014201620182020202220242025
Compound annual growth
−28.2%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2023 · Operating -55519.9% · Net -54858.1%
-20000%-40000%201020122014201620182020202220242025
ROE
FY2025 · ROE -243.9%
-1000%-2000%201020122014201620182020202220242025

Each USD of equity lost 244 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -15.4
-8M201020122014201620182020202220242025
Net buybacks $ Dividends $
FY2011 · Dividends — · Net buybacks 3751.0
20002011

Total assetsUSD 10.1M
EquityUSD 8.3M
CashUSD 4.4M

Equity funds 82% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B··0.00.00.0···0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B··············−0.0−0.0
Income tax $B−0.0······0.00.00.00.00.00.0··−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B···−0.0−0.0·−0.0−0.0·−0.0−0.0−0.0−0.0−0.0·−0.0
EPS, diluted $−4.56−47.88−9.18−7.11−0.14−0.47−0.37−0.87−1.37−1.57−0.32−0.16−0.56−0.74−1.34−1.42
Dividend / sh $················
Payout %················
ROE %−243.9−714.9−255.4−72.4−72.5−155.1−81.7−72.9−145.0−182.2−155.5−44.2−128.2−2487.9··
Shares out B0.000.000.000.000.000.090.050.030.000.000.040.040.040.030.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 69 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 24 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inFlorida
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image